Brokerages Set Stoke Therapeutics, Inc. (NASDAQ:STOK) Price Target at $20.57

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been given a consensus rating of “Moderate Buy” by the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $20.57.

STOK has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, May 7th. Wedbush lifted their price objective on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the stock an “outperform” rating in a report on Tuesday, March 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a report on Thursday, April 4th. Canaccord Genuity Group lowered their price target on shares of Stoke Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, May 7th. Finally, TD Cowen raised shares of Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 26th.

Insider Activity

In other news, major shareholder Skorpios Trust sold 3,600,000 shares of the company’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $11.60, for a total transaction of $41,760,000.00. Following the completion of the transaction, the insider now directly owns 10,843,681 shares of the company’s stock, valued at $125,786,699.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of STOK. State Board of Administration of Florida Retirement System bought a new position in Stoke Therapeutics in the first quarter worth about $141,000. Sherbrooke Park Advisers LLC bought a new position in Stoke Therapeutics in the third quarter worth about $48,000. BNP Paribas Financial Markets raised its stake in Stoke Therapeutics by 86.2% in the first quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company’s stock worth $193,000 after buying an additional 6,636 shares in the last quarter. Corton Capital Inc. bought a new position in Stoke Therapeutics in the third quarter worth about $58,000. Finally, Public Employees Retirement System of Ohio bought a new position in Stoke Therapeutics in the third quarter worth about $64,000.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK opened at $12.92 on Thursday. Stoke Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $17.58. The stock has a market cap of $673.40 million, a price-to-earnings ratio of -5.36 and a beta of 0.88. The firm’s 50-day simple moving average is $13.73 and its 200 day simple moving average is $9.27.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Monday, May 6th. The company reported ($0.57) earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.03. The business had revenue of $4.22 million during the quarter, compared to the consensus estimate of $3.33 million. On average, sell-side analysts predict that Stoke Therapeutics will post -2.3 EPS for the current year.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.